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Context: The genetic background of young-onset Graves disease (GD) remains largely 
unknown. An intronic variant in human leukocyte antigen (HLA) complex P5 (HCP5) has 
previously been associated with GD susceptibility and age of onset in a cohort of Polish patients.
Objective: We aimed to investigate the association of the HCP5 variant rs3094228 with GD 
susceptibility and age of onset in a UK cohort and conduct a meta-analysis of UK and Polish data.
Design and Participants: rs3094228 was genotyped in 469 UK patients with GD using Taqman chemistry. 
Genotype frequencies were compared with genotypic data available from the Wellcome Trust case-
control consortium using logistic regression analysis. To determine whether rs3094228 is independently 
associated with age of GD onset, the HLA DRB1*0301 tagging variant, rs535777, was also genotyped.
Results: The C allele of rs3094228 was overrepresented in the UK GD cohort compared with controls 
(P allele=5.08 × 10–9, odds ratio 1.76; [95% confidence interval, 1.46-2.13]). This association was more 
marked in young-onset GD (<30 years) (P allele=1.70 × 10–10 vs P allele=0.0008). The meta-analysis of UK 
and Polish data supported the association of the C allele with GD susceptibility (P allele=1.79 × 10–5) 
and age of onset (P allele=5.63 × 10–8). Haplotype analysis demonstrated that rs3094228 is associated 
with age of GD onset (P = 2.39 × 10-6) independent of linkage disequilibrium with HLA DRB1*0301.
Conclusion: The rs3094228 HCP5 polymorphism is independently associated with GD 
susceptibility and age of onset in a UK GD cohort. Our findings indicate a potential role of long 
noncoding ribonucleic acids, including HCP5, in GD pathogenesis, particularly in the younger 
population. (J Clin Endocrinol Metab 105: 1–8, 2020)
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G raves disease (GD) is the most common cause of hyperthyroidism in young children and adoles-
cents; however, it is still relatively rare, with a reported 
incidence of between 0.1 and 3 per 100 000 (1) com-
pared with Caucasian European adults where the inci-
dence is reported as 20 to 25 cases per 100 000 (2, 3). 
Longitudinal studies have reported an increasing inci-
dence of hyperthyroidism in both adult and pediatric 
populations 4-6). Similar to other autoimmune condi-
tions, there is a clear female preponderance, with GD 
affecting up to 3% of women and 0.5% of men, with 
a peak incidence occurring between 30 and 50 years of 
age (2).
GD is characterized by the presence of thyroid receptor 
autoantibodies (TRAbs) that stimulate the cell-surface 
thyroid-stimulating hormone (TSH) receptor, directly re-
sulting in excessive, autonomous thyroid hormone secre-
tion. The clinical features and prognosis of GD is highly 
variable depending on age of disease onset, with the re-
mission rate following a course of antithyroid medication 
being as low as 25% in the pediatric population compared 
with 50% to 60% in adults (7, 8).
GD results from a complex interaction between gen-
etic and environmental factors involving variants in 
multiple susceptibility genes, each exerting modest in-
dividual effects. Family and twin studies over the past 
50  years have demonstrated that up to 80% of an 
individual’s predisposition to GD is attributable to gen-
etic factors (9, 10). However, only around 20% of this 
genetic load has been accounted for by the currently as-
sociated genomic variants (11).
Genomic polymorphisms associated with suscepti-
bility to GD are primarily found at immune-regulatory 
loci, such as MHC (12), CTLA-4 (13), PTPN22 (14), 
and CD40 (15). A  stronger genetic association is sus-
pected in the younger population who have had less ex-
posure to environmental factors. Several of the known 
susceptibility loci are also associated with a younger 
age of disease onset, including those at CTLA-4 (16), 
human leukocyte (HLA)-DRB1 (17), and PTPN22 (18), 
with the most strongly associated variants located at the 
major histocompatibility complex (MHC) locus (19, 
20). Determining genetic variants associated with GD 
can provide mechanistic insight by highlighting patho-
genic functional pathways, particularly by studying the 
younger population where genetics may be the dominant 
factor (19).
This study aimed to investigate the association of 
the HLA complex P5 (HCP5) gene in GD susceptibility 
and age of onset in a UK cohort. The association be-
tween HCP5 variants and thyroid autoimmunity was 
first demonstrated in a multicenter population-based 
genome-wide association study conducted by Medici 
et al for serum levels of thyroid peroxidase antibodies 
(21). The first study showing an association of HCP5 
with susceptibility to GD (rs3094228, P = 1.6 × 10–12; 
odds ratio [OR] = 1.88), was performed in a single 
center by Kuś et al (22). A subsequent multicenter study 
with a relatively large pediatric GD cohort demon-
strated the HCP5 variant, rs3094228, as a risk locus for 
young-onset GD (YOGD) (23).
We have studied the same HCP5 polymorphism in a 
UK GD cohort and performed a meta-analysis of data 
from the UK and Polish patient cohorts.
Materials and Methods
Participants
A total of 469 patients were included in the UK cohort, 
including 118 patients with YOGD (aged <30  years) and 
351 patients with unrelated later-onset GD (LOGD) (aged 
≥30 years). The YOGD cohort included 18 (15%) male and 
100 (85%) female (GD onset aged 3-29 years; median 22 years, 
mean 20.8 years) and the LOGD cohort included 55 (16%) 
male and 296 (84%) female (GD onset aged 30-92 years; me-
dian 47 years, mean 48.2 years).
The patients providing these samples were of Caucasian 
European background and had attended outpatient endo-
crinology at the Royal Victoria Infirmary or the Great North 
Children’s Hospital, Newcastle-upon-Tyne, UK. Each partici-
pant with GD was diagnosed by the following criteria: fully 
suppressed serum TSH with serum free thyroxine and/or free 
triiodothyronine above the reference range and the existence 
of detectable TSH receptor antibody (TRAb; ≥1.8 mU/L; 
Brahms Kryptor).
Genotype data from 5377 control samples from the 
Wellcome Trust case-control consortium (WTCCC2) data-
base were used for comparison. Informed, written consent 
was obtained from all participants. This study was carried 
out with approval of the Leeds East (Ref. 05/Q1206/144) and 
Berkshire Valley ethics committees (Ref. 04/12/015).
HCP5 genotyping
The HCP5 variant rs3094228 was genotyped in genomic 
deoxyribonucleic acid extracted from venous blood using 
TaqMan chemistry as per the manufacturer’s instructions 
(assay C_2995657_10) and run on the QuantStudio 7 Flex 
Real-Time PCR (polymerase chain reaction) System (Applied 
Biosystems). Twenty percent of the samples were genotyped in 
duplicate to ensure assay fidelity. The overall genotyping call 
rate was 99.8%.
HLA genotyping
The HLA DRB1*0301 tagging variant, rs535777, was 
genotyped in the UK cohort as above (assay C__26546461_30). 
The overall genotyping call rate was 99.6%.
In the Polish cohort, the HLA-DRB1 polymorphism was 
genotyped using the low-resolution single specific primer-
polymerase chain reaction (SSP-PCR) method with use of the 
Dynal All Set SSP DR Kit or the HLA-Ready Gene DR Kit, as 
previously described (22).
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Statistical analysis
Statistical association analysis was performed using PLINK 
(24) and SPSS version 25 (25). All the control sample geno-
types were in Hardy-Weinberg equilibrium (P > 0.4). Study 
data were compared with WTCCC2 control data using lo-
gistic regression with sex as a covariate. A subgroup associ-
ation analysis was performed comparing young-onset (aged 
<30 years) GD to older-onset (aged ≥ 30 years) GD. A meta-
analysis, using the Review Manager (RevMan) Version 5.0 
program (Nordic Cochrane Centre, Copenhagen, Denmark 
(26)) was then undertaken, using a random effects model to 
calculate ORs, 95% confidence intervals (CI) and 2-sided P 
values. The impact of heterogeneity between the cohorts was 
estimated using an I2 index. Kaplan-Meier plots and log-rank 
tests were applied to determine whether genotype was signifi-
cantly associated with age of GD onset. Logistic regression and 
haplotype analysis (UNPHASED 3.1.7 (27)) was performed to 
determine the independent association of rs3094228 with age 
of GD onset.
Results
GD susceptibility
The minor C allele and the CC genotype at rs3094228 
are associated with susceptibility to GD. The frequency 
of the C allele was significantly increased in the GD 
cohort as a whole (303/938; 32%) compared with 
WTCCC2 controls (2118/10 754; 20%: P = 5.08 × 10–
9; OR 1.76 [95% CI, 1.46-2.13]). There was also a sig-
nificant increase in the CC genotype in the GD group 
(39/469; 8%) compared with WTCCC2 controls 
(219/5377; 4%: P = 2.89 × 10–18) (Table 1).
GD age of onset
Although an increased frequency of the C allele 
was present in both the YOGD (99/236; 42%) and 
LOGD groups (204/702; 29%) compared with controls 
(2118/10 754; 20%), the difference was more signifi-
cant in the YOGD group (P = 1.70 × 10–10; OR 2.73 
[95% CI, 2.00-3.71]) compared with the LOGD cohort 
(P = 0.0008; OR 1.49 [95% CI, 1.18-1.88]). In add-
ition, a significant increase in the frequency of the C 
allele (99/236; 42% vs 204/702; 29%: Pallele=0.00025; 
OR 1.76 [95% CI, 1.3-2.4]) and CC genotype (16/118; 
13% vs 23/351; 7%: Pgenotype=0.00059) was observed 
in the YOGD group when compared with the LOGD 
cohort (Table 2). This suggests that the C allele and CC 
genotype have a stronger association with susceptibility 
to GD at a younger age.
Meta-analysis
A meta-analysis was undertaken using additional 
genotype data provided by Kuś et al (22) from a study 
that examined genetic risk loci including rs3094228 in 
a Polish GD cohort. The YOGD Polish cohort (aged 
<30  years) included 66 (19%) male and 280 (81%) 
female (GD onset aged 3-29  years; median 18  years, 
Table 1. Logistic regression analysis with sex as a covariate. Genotype and allele frequencies at rs3094228 
in the GD UK cohort and healthy Controls (WTCCC2), subdivided into age of disease onset (aged < 30 years 
/ ≥ 30 years)
rs3094228
WTCCC  
Controls (%) All GD UK Cohort (%)
GD Aged  
< 30 Years (%)
GD Aged  
≥ 30 Years (%)
Genotype frequency CC 219 (4) 39 (8) 16 (13) 23 (7)
CT 1680 (31) 225 (48) 67 (57) 158 (45)
TT 3478 (65) 205 (44) 35 (30) 170 (48)
P value   2.89 × 10–18 1.90 × 10–13 6.97 × 10–9
Allele frequency C 2118 (20) 303 (32) 99 (42) 204 (29)
T 8636 (80) 635 (68) 137 (58) 498 (71)
P value  
(OR [95% CI])
  5.08 × 10–9  
(OR 1.76 [1.46-2.13])
1.70 × 10-10  
(OR 2.73 [2.00-3.71])
0.0008  
(OR 1.49 [1.18-1.88])
Abbreviations: CI, confidence interval; GD, Graves disease; OR, odds ratio; WTCCC, Wellcome Trust case-control consortium.
Table 2. Association analysis of sex-matched young-onset (aged < 30 years) GD compared with later-onset 
(aged ≥ 30 years) GD
rs3094228 GD Aged < 30 Years (%) GD Aged ≥ 30 Years (%)
Genotype frequency CC 16 (13) 23 (7)
CT 67 (57) 158 (45)
TT 35 (30) 170 (48)
P value   0.00059
Allele frequency C 99 (42) 204 (29)
T 137 (58) 498 (71)
P value  
(OR [95% CI])
  0.00025  
(OR 1.76 [1.3-2.4])
Abbreviations: CI, confidence interval; GD, Graves disease; OR, odds ratio.
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mean 19  years), and the LOGD Polish cohort (aged 
≥ 30 years) included 194 (22%) male and 672 (78%) 
female (GD onset aged 30-81 years; median 47 years, 
mean 48 years).
Using a random effects model, the association of the 
C allele with susceptibility to GD (P = 1.79 × 10–5; OR 
1.71 [95% CI, 1.34-2.19]) and an earlier age of disease 
onset YOGD versus LOGD (P = 5.63 × 10–8; OR 1.56 
[95% CI, 1.33-1.83]) was confirmed (Fig. 1A).
Using the combined UK and Polish cohorts, Kaplan-
Meier plots and log-rank tests demonstrated a signifi-
cant association with genotype and age of GD onset, 
confirming the association of the CC genotype with 
earlier-onset GD (P = 0.003) (Fig. 1B). In addition, a re-
cessive model demonstrated an increased risk of earlier-
onset GD in homozygotes for the minor allele compared 
with carriers for the common allele (P = 0.001). The me-
dian age of GD onset in those with the CC genotype was 
34 years compared with 40 and 43 years with the CT 
and TT genotypes, respectively.
Haplotype analysis
To determine whether the effect of rs3094228 on age 
of GD onset is independent of the common GD sus-
ceptibility locus, HLA DRB1*0301, a gender-adjusted 
logistic regression analysis on the Polish data was 
undertaken, including 439 patients with GD with avail-
able data on HLA DRB1*03, rs3094228, and age of 
GD onset. This demonstrated that the observed effect 
of rs3094228 on age of GD onset is independent from 
HLA DRB1*03 (P = 0.006).
This was further studied in the UK GD cohort using a 
known tagging single nucleotide polymorphism for HLA 
DRB1*0301 in the Northern and Western European 
(CEU) population (rs535777; r2=0.87, D’=0.99) (28). 
Consistent with the Polish data, a gender-adjusted 
Figure 1. Age-associated cumulative incidence of Graves disease (GD) onset associated with the rs3094228 polymorphism. (A) Forest plot of 
meta-analysis results in GD susceptibility and age of onset in UK and Polish cohorts: meta-analysis using a random effects model of rs3094228 in 
the HCP5 gene examining GD susceptibility compared with controls, and YOGD compared with LOGD. (B) Kaplan-Meier analysis and log-rank test. 
The CC genotype was associated with earlier-onset GD. CI, confidence interval; LOGD, later-onset Graves disease (aged ≥30 years); YOGD, young-
onset Graves disease (aged <30 years). Abbreviation: M-H, Mantel-Haenszel test.
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logistic regression analysis on the UK cohort demon-
strated that the effect of rs3094228 on age of GD onset 
occurs independently of HLA DRB1*0301 (P = 0.004). 
A  combined logistic regression analysis including the 
Polish and UK cohorts (906 patients) demonstrated that 
the interaction of HCP5 and HLA DRB1*0301 was sig-
nificantly associated with age of GD onset (P = 0.046) 
(Table  3). Haplotype analysis with HCP5 as the test 
marker and HLA DRB1*0301 as the conditioning 
marker demonstrated that HCP5 is independently asso-
ciated with age of GD onset (P = 2.39 × 10-6).
Discussion
This meta-analysis includes more than 1600 partici-
pants with GD, including more than 460 early-onset 
cases, from UK and Polish populations. Given the 
relative rarity of GD in the pediatric population, com-
bining genotype data sets is essential to improve study 
power. Despite the established strong hereditary com-
ponent of GD, particularly in the development of GD 
at a younger age, there is limited data documenting 
genetic risk variants specifically accounting for YOGD 
(19, 29, 30). This study finds a robust association 
between susceptibility to GD and an earlier age of 
disease onset with an intronic HCP5 polymorphism in 
a UK cohort, replicating previous findings in a Polish 
population (23).
The HCP5 ribonucleic acid (RNA) gene is located 
within the MHC class  I  region, centromeric of the 
HLA-B gene between the MICA and MICB genes, 
and it encodes a long noncoding RNA (lncRNA) (31). 
MHC genes encode cell-surface antigen-presenting 
proteins that are essential to mount an autoimmune 
response. Genome-wide association studies have iden-
tified polymorphisms at the MHC locus as risk vari-
ants for many autoimmune and inflammatory diseases, 
including GD in both Asian and European populations 
(32, 33). Furthermore, Immunochip genetic analysis has 
demonstrated that variants within the MHC have the 
strongest association with YOGD (aged <30 years) (19).
The role of the MHC class  II region is well estab-
lished in GD, where antigen presentation of thyroid-
stimulating hormone receptor to CD4 + T cells is 
crucial to drive the B cells to produce the pathogenic 
TRAb autoantibodies (34). However, genetic variants 
in the MHC I  region (HLA-B and HLA-C) have also 
previously been independently associated with GD (35). 
Indeed, messenger RNAseq analysis of GD thyroid 
tissue found that HLA-C in the MHC I region was the 
most overexpressed gene compared with controls (36). 
The primary function of MHC I molecules is to present 
nonself antigens derived from intracellular sources, such 
as viruses, to CD8 + cytotoxic T cells, which then mount 
a cytotoxic response against the presented antigen. It 
has been proposed that viruses may trigger an auto-
immune response through molecular mimicry where 
viral antigens are structurally similar to self-antigens, 
or bystander activation where the viral infection trig-
gers a nonspecific activation of autoreactive cells (37). 
Various HCP5 variants are demonstrated to promote 
susceptibility to adverse immune-related cutaneous 
drug reactions, such as Stevens-Johnson syndrome, as 
well as being associated with disease progression and 
viral load in untreated patients with HIV, suggesting 
a possible specific role for HCP5 in modifying the im-
mune response to medications or viral infections (38, 
39). Certain genetic variants within the MHC I region, 
such as HCP5 polymorphisms, may predispose to GD 
by modifying an individual’s response to an infectious 
agent, resulting in an excessive immune response with 
the potential to initiate an autoimmune reaction in gen-
etically susceptible individuals.
The HCP5 polymorphism rs3094228 investigated in 
this study has previously been associated with suscepti-
bility to GD in a Polish cohort (22), and an association 
has been demonstrated between the C allele and thy-
roid peroxidase antibody levels in autoimmune thyroid 
disease (21). Other HCP5 variants have been associ-
ated with susceptibility and autoantibody production in 
various autoimmune disorders, including systemic lupus 
erythematous (40), Sjögren syndrome (41), psoriasis, 
and psoriatic arthritis (42).
Table 3. Logistic regression analysis of rs3094228 and HLA DRB1*03, using the combined UK and Polish 
cohorts 
Polymorphism B SE P Value OR (95% CI)
rs3094228 0.330 0.151 0.028 1.39 (1.04-1.87)
HLA DRB1*03 /  
rs535777
–0.497 0.200 0.013 0.61 (0.41-0.90)
rs3094228 +  
HLA DRB1*03 /  
rs535777 
0.389 0.195 0.046 1.48 (1.01-2.17)
rs535777 was used as tagging variant for the HLA DRB1*0301 locus in the UK cohort.
Abbreviations: B, unstandardized regression coefficient; CI, confidence interval; OR, odds ratio; SE, standard error.
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The MHC gene region is highly polymorphic and 
characterized by extended linkage disequilibrium (LD), 
making it challenging to determine functional vari-
ants from tagging single nucleotide polymorphisms, 
which highlights the importance of rigorous case-
control matching in genetic association studies. LD 
analysis indicates that the known GD risk locus, HLA 
DRB1*03, and rs3099844 studied in systemic lupus 
erythematous and Sjögren syndrome, are in partial LD 
with rs3094228 (HLA DRB1*03: r2 =0.45, D’ =0.86 
in the Polish population (22), rs3099844: r2 =0.69, D’ 
=0.93 in the British population (28)). However, our 
haplotype analysis with HLA DRB1*03 demonstrates 
that HCP5 is independently associated with age of 
GD onset.
Interestingly, there is accumulating evidence sug-
gesting that lncRNA, such as HCP5, has a crucial role 
in the development of autoimmunity by altering the 
adaptive and innate immune response through tran-
scriptional and epigenetic regulation (32, 43-45). 
Studies have demonstrated that lncRNAs are asso-
ciated specifically with autoimmune thyroid disease 
(AITD), including GD. Indeed, it has been proposed 
that rs3094228 alters the expression of thyrocyte lig-
ands (MICA, MICB and HLA-C) of immunoreceptors 
on natural killer cells in those with AITD, promoting 
antibody-dependent natural killer cell-mediated cyto-
toxicity of the thyrocyte (46), making it a potentially 
functional variant. Furthermore, a study by Shirasawa 
et  al demonstrated that a polymorphism in the pro-
moter region of a B-cell-specific antisense RNA tran-
script, SAS-ZFAT, is associated with susceptibility to 
AITD (44), and the lncRNA transcript, Heg, has dem-
onstrated negative correlation with TRAb concentra-
tions in untreated patients with GD (47). Although the 
precise mechanism remains to be determined, this sug-
gests that both variation and dysregulation of lncRNAs 
are implicated in AITD, including GD.
HCP5 is expressed at high levels in cells of the im-
mune system such as the spleen, blood, and thymus (48). 
The aging immune system may contribute to the pheno-
typic differences observed between YOGD and LOGD, 
where involution of the thymus and reduced B- and 
T-lymphocyte production may alter the mechanisms 
driving the autoimmune response in the older popula-
tion (49). Phenotypic differences may also be explained 
by genetic variation including those in the MHC region 
(HLA subtypes DB1*02, DQA1*05, and DRB1*03), 
which have been associated with a higher risk of relapse 
in GD (50).
As this study was performed in a Caucasian popula-
tion, further studies are required to investigate whether 
a similar effect is also detected in other (non-Caucasian) 
populations. Further functional studies should also aim 
to elucidate the underlying mechanism behind the ob-
served association.
Conclusion
This study has confirmed a significant association of the 
HCP5 polymorphism, rs3094228, with GD suscepti-
bility and age of disease onset in a UK cohort and rep-
licates the findings from a study of patients with GD 
in Poland. Adult-onset and young-onset GD share mul-
tiple common genetic risk variants, many of which re-
main unknown. Our findings indicate a potential role 
for HCP5 as a contributor to GD susceptibility, particu-
larly in the younger population. Further research to de-
termine the role of lncRNAs, including HCP5, in the 
pathogenesis of early-onset GD is now warranted.
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